Verastem (VSTM) said late Thursday that the metastatic pancreatic ductal adenocarcinoma patients treated with avutometinib or Avmapki plus defactinib in combination with standard-of-care chemotherapy achieved an overall response rate of 83% as of April 25.
Under the RAMP 205 phase 1/2 trial, the company said 60 patients were treated in one of five dose regimens with the combination of avutometinib and defactinib with gemcitabine and nab-paclitaxel in frontline metastatic PDAC.
The trial showed positive safety and efficacy results, with adverse events remaining generally consistent with the previously announced safety and tolerability profile, the company said.
Verastem said it plans to register a phase 3 front-line metastatic PDAC trial, expected to start in 2026.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.